Cannabics appoints Shaul Yemal to Board as independent director and Audit Committee member

CNBX Pharmaceuticals Inc.

Board expanded to five members; Shaul Yemal appointed as independent director and Audit Committee member.
Yemal brings transnational finance experience, including roles at Israeli Ministry of Finance and Ministry of Energy.
Previously CEO of ICL Santiago, Senior VP at ISAL Amlat VC Fund, and catalyst for Oridion Medical's IPO on Swiss exchange.
No arrangements or understandings with any other person; no related party transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Shaul Yemal

Independent Director

CNBX · CNBX Pharmaceuticals Inc.

Effective: 2021-11-16
Filed: November 19, 2021, 6:59 PM ET

On November 16 th , 2021, the Board of Directors (the “Board”) increased the size of the Board to five (5) members, and appointed Mr. Shaul Yemal to the Board as an Independent Director and as a member of the Audit Committee.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shaul Yemal was appointed as Independent Director at CNBX Pharmaceuticals Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

On November 16 th , 2021, the Board of Directors (the “Board”) increased the size of the Board to five (5) members, and appointed Mr. Shaul Yemal to the Board as an Independent Director and as a member of the Audit Committee.

View on SEC.gov

CNBX Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001683168-21-005846

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.